POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL

Abstract

BackgroundGiven the chronic nature of psoriatic arthritis (PsA), understanding long-term efficacy and safety of biologic monotherapy or therapy in combination with ongoing methotrexate (MTX) is of interest. Studies have shown...